DEXTECH MEDICAL AB
NNGM:DEX10.25
SEK
+0.05
(+0.49%)
ISIN
SE0005881489
Return %
Stock
S&P 500
1Y
41.38
14.20
3Y
141.75
81.12
5Y
-50.14
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Anders Ragnarson Holmberg
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Uppsala Sweden
- IPO Date
- Jun 19, 2014
- Website
- dextechmedical.com
- Similar Companies
- Business
- DexTech Medical AB is a Swedish clinical-stage biotechnology company founded in 2004 and headquartered in Uppsala, Sweden, specializing in the research and development of targeted therapies for oncology, with a primary focus on urological malignancies, hematological cancers, and bone metastases. The company utilizes its proprietary, patented carbohydrate-drug conjugate technology platform, GuaDex, a biocompatible dextran-based delivery system engineered to selectively deliver therapeutic payloads to malignant cells while minimizing systemic toxicity. DexTech Medical AB's proprietary product pipeline comprises OsteoDex (ODX), a lead dual-action conjugate combining a dextran backbone with a bisphosphonate and a cytotoxic agent for the treatment of bone metastases in castration-resistant prostate cancer, multiple myeloma, breast cancer, and lung cancer; SomaDex, a therapeutic conjugate based on the endogenous hormone somatostatin-14 designed for the treatment of acromegaly, neuroendocrine tumors, and palliative care in advanced prostate cancer; PSMA-Dx, a targeted platform utilizing a prostate-specific membrane antigen-binding peptide coupled to GuaDex for the delivery of radionuclides and chemotherapeutic payloads; and CatDex, a cytotoxic carbohydrate conjugate developed for targeted anti-tumor cell efficacy. The company operates a business model focused on translational drug development through Phase II clinical trials, aiming to out-license candidates and establish strategic co-development alliances with international pharmaceutical corporations for late-stage development and commercial distribution. In recent developments, DexTech Medical AB completed the treatment and follow-up phases of its Phase I/IIa clinical trial evaluating OsteoDex in relapsed and refractory multiple myeloma, successfully meeting primary safety endpoints and demonstrating clinical disease stabilization. Furthermore, the company expanded its intellectual property portfolio through the grant of a European patent covering the Good Manufacturing Practice manufacturing process for OsteoDex, providing market and production exclusivity through 2045 to strengthen commercial out-licensing negotiations. DexTech Medical AB is publicly traded on the Spotlight Stock Market in Sweden under the ticker symbol DEX.